Barr gets tentative FDA approval to market generic Allegra-D

07/6/2004 | NYTimes.com

Barr Laboratories said it received tentative FDA approval to market a generic brand of Aventis' allergy drug Allegra-D, but final approval is contingent on settlement of lawsuits between Aventis and five firms that seek to market generic brands of the drug. Barr applied in 2001 for permission to sell its generic version, but observers predict that trials of the pending lawsuits will not take place until April 2005.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA